In a statement, the company said, "Our products have been widely recognized by hospitals, clinics and diagnostic centers, and we have continued to innovate in order to provide more efficient and cost-effective solutions for healthcare providers and patients."
The company already offers a range of rapid tests for infectious diseases including HIV, chlamydia, gonorrhea, syphilis and hepatitis B and C. The new test, which will detect multiple STDs in a single test, will help healthcare providers to quickly and accurately diagnose infections which are often difficult to detect.
STDs are a serious and growing public health concern in many parts of the world, with an estimated 376 million new cases each year. The World Health Organization (WHO) has identified STDs as one of the top 13 global health challenges, and has called for increased investment in prevention, testing and treatment.
The new rapid test from Nanjing Liming Bio-products Co., Ltd. will be an important tool in the fight against STDs, offering rapid and accurate diagnosis and reducing the spread of infections. The company's commitment to innovation and quality will continue to drive improvements in healthcare outcomes, benefiting patients and healthcare providers alike.
In addition to its new STD rapid test, the company has also developed a range of other products for infectious diseases, including rapid tests for influenza, tuberculosis, malaria, and Zika virus.
"By investing in research and development, and working closely with healthcare providers, we are continually improving our products and services to meet the evolving needs of the global health community," said the company in its statement.
With its focus on innovation, quality and affordability, Nanjing Liming Bio-products Co., Ltd. is well positioned to play a leading role in the fight against infectious diseases around the world.